Supp. Figure 1



Supp Figure 1. Sensitivity to BH10 is not altered by inhibitors of necroptosis, ferroptosis or PARP. The necroptosis inhibitors, necrostatin (RIPK1 inhibitor) (A) and necrosulfonamide (MLKL inhibitor) (B), and ferroptosis inhibitor (ferrostatin) (C), do not protect against BH10-induced death in HEC1A cancer cells. (D) The PARP inhibitor, olaparib, does not alter sensitivity to BH10 in HEC1A cancer cells. Cells were pre-treated with the indicated doses of each inhibitor for 15-30 minutes prior to the addition of BH10. Total incubation times were 48 hours. n≥3 for all experiments. Data represent mean±SEM.

Supp. Figure 2



Supp Figure 2. BH10 does not significantly alter PRDX2 dimerisation. Representative western blot of peroxiredoxin 2 (PRDX2) dimerization in MAD11 and HEC1A cells treated with vehicle (DMSO), BH10 (20 µM), or BH10 in combination with GSH (2 mM) (150-minute treatment). 14-3-3 serves as a protein loading control. Graph shows quantification of ratio of PRDX2 dimer to monomer (band densitometry) for each condition shown in western blot. Data represent mean±SEM.